Gilead Cornered Into Expanding Access To HIV, Hep C Drugs in Malaysia, Other Countries
Executive Summary
Faced with the prospect of a compulsory license in Malaysia, Gilead has reviewed its generic licensing agreements to grant access to low-cost versions of its HIV and hepatitis C drugs in the country and three other middle-income nations.
You may also be interested in...
Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies
Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
By marketing its own authorized generic versions of blockbuster HCV combos Epclusa and Harvoni, Gilead may eat into AbbVie’s large market share edge in US government-insured patients.